Literature DB >> 9851798

Expression of type 2 11beta-hydroxysteroid dehydrogenase and corticosteroid hormone receptors in early human fetal life.

J Condon1, C Gosden, D Gardener, P Nickson, M Hewison, A J Howie, P M Stewart.   

Abstract

In adult life, the type 2 isozyme of 11beta-hydroxysteroid dehydrogenase (11betaHSD2) protects the mineralocorticoid receptor (MR) from glucocorticoid by inactivating cortisol to cortisone. 11betaHSD2 activity has been reported in human fetal tissues, where glucocorticoids may impair fetal growth yet are also required for normal fetal development. Using digoxigenin-labeled complementary ribonucleic acid (RNA) probes and an in-house 11betaHSD2 antiserum, we have analyzed the expression of 11betaHSD2, MR, and glucocorticoid receptor (GR) in human fetal tissues of gestational age 6-17 weeks (n=15). 11BetaHSD2 expression was absent at gestational age 6+ weeks, but was expressed in abundance in many fetal tissues between 8-12 weeks. At this time, 11betaHSD2 colocalized with GR messenger RNA (mRNA) expression in metanephros, gut, muscle, spinal cord and dorsal root ganglia, periderm, sex chords of testis, and adrenal. In particular within fetal kidney, intense expression of 11betaHSD2 and GR mRNA was observed over Bowman's capsule and the vascular tufts of developing glomeruli as they migrated from the surface of the kidney to the inner cortex. Only lung and adrenal medullary rests demonstrated high levels of GR mRNA but low levels of 11betaHSD2. 11BetaHSD2 mRNA and immunoreactivity staining patterns were similar, with the exception of the fetal adrenal, where mRNA was localized to the outer definitive zone but immunoreactivity was localized to the inner fetal zone. Colocalization of 11betaHSD2 (and GR mRNA) with MR mRNA was observed principally within epithelial cells of collecting ducts, particularly after 16 weeks gestation when the pattern of distribution of 11betaHSD2 became more adult in nature. High levels of MR mRNA were observed within developing bone. The data indicate that 11betaHSD2 in fetal life principally modulates ligand access to the GR in most fetal tissues, notably glomeruli and tubules in the developing kidney, testis, and periderm, and this may be have ramifications for fetal sodium homeostasis and differentiation. The development of tissues previously shown to have a critical requirement for glucocorticoids, such as lung and adrenal medulla, is facilitated by the expression of GR mRNA, but not 11betaHSD2. The expression of MR mRNA in high abundance in bone suggests a role for corticosteroids in human bone development, and the low/absent expression of 11betaHSD2 at this site suggests that it is functionally acting as a GR.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851798     DOI: 10.1210/jcem.83.12.5302

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

Review 1.  Genetic approaches to determine the role of glucocorticoid signaling in osteoblasts.

Authors:  John R Harrison; Henning W Woitge; Barbara E Kream
Journal:  Endocrine       Date:  2002-02       Impact factor: 3.633

Review 2.  Fetal programming of hypothalamo-pituitary-adrenal function: prenatal stress and glucocorticoids.

Authors:  Amita Kapoor; Elizabeth Dunn; Alice Kostaki; Marcus H Andrews; Stephen G Matthews
Journal:  J Physiol       Date:  2006-02-09       Impact factor: 5.182

Review 3.  The glucocorticoid receptor and its expression in the anterior pituitary and the adrenal cortex: a source of variation in hypothalamic-pituitary-adrenal axis function; implications for pituitary and adrenal tumors.

Authors:  George Briassoulis; Svetozar Damjanovic; Paraskevi Xekouki; Hervé Lefebvre; Constantine A Stratakis
Journal:  Endocr Pract       Date:  2011 Nov-Dec       Impact factor: 3.443

4.  Fetal growth restriction alters transcription factor binding and epigenetic mechanisms of renal 11beta-hydroxysteroid dehydrogenase type 2 in a sex-specific manner.

Authors:  Mariana Baserga; Rajwinderjit Kaur; Merica A Hale; Allyson Bares; Xing Yu; Christopher W Callaway; Robert A McKnight; Robert H Lane
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-04-28       Impact factor: 3.619

5.  A role for mineralocorticoid receptors in the physiology of the ovine fetus: effects on ACTH and lung liquid composition.

Authors:  Maureen Keller-Wood; Charles E Wood; Jarret McCartney; Nathan M Jesse; Dana Perrone
Journal:  Pediatr Res       Date:  2011-06       Impact factor: 3.756

6.  Stress-related programming of autonomic imbalance: role in allergy and asthma.

Authors:  Rosalind J Wright
Journal:  Chem Immunol Allergy       Date:  2012-06-26

Review 7.  Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis.

Authors:  Elise P Gomez-Sanchez
Journal:  Steroids       Date:  2014-12       Impact factor: 2.668

8.  Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone.

Authors:  Maria Fleseriu; James W Findling; Christian A Koch; Sven-Martin Schlaffer; Michael Buchfelder; Coleman Gross
Journal:  J Clin Endocrinol Metab       Date:  2014-07-11       Impact factor: 5.958

9.  Low renal mineralocorticoid receptor expression at birth contributes to partial aldosterone resistance in neonates.

Authors:  Laetitia Martinerie; Say Viengchareun; Anne-Lise Delezoide; Francis Jaubert; Martine Sinico; Sophie Prevot; Pascal Boileau; Geri Meduri; Marc Lombès
Journal:  Endocrinology       Date:  2009-05-28       Impact factor: 4.736

Review 10.  New insight on the molecular aspects of glucocorticoid effects in nervous system development.

Authors:  R Maggi; D Dondi; M Piccolella; L A Casulari; L Martini
Journal:  J Endocrinol Invest       Date:  2013-06-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.